IFRX Valuation

Add to Watchlist

Advanced Chart

0.000

0(0.000%)1D

IFRX Relative Valuation

IFRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IFRX is overvalued; if below, it's undervalued.

Historical Valuation

InflaRx NV (IFRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.09 is considered Undervalued compared with the five-year average of -2.45. The fair price of InflaRx NV (IFRX) is between 141.38 to 776.19 according to relative valuation methord. Compared to the current price of 1.37 USD , InflaRx NV is Undervalued By 99.03%.

Relative Value

Fair Zone

141.38-776.19

Current Price：1.37

99.03%

Undervalued

-2.11

Trailing

Forward

0.00

EV/EBITDA

InflaRx NV. (IFRX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.13. The thresholds are as follows: Strongly Undervalued below -7.33, Undervalued between -7.33 and -4.23, Fairly Valued between 1.97 and -4.23, Overvalued between 1.97 and 5.07, and Strongly Overvalued above 5.07. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.48

EV/EBIT

InflaRx NV. (IFRX) has a current EV/EBIT of -0.48. The 5-year average EV/EBIT is -1.09. The thresholds are as follows: Strongly Undervalued below -3.59, Undervalued between -3.59 and -2.34, Fairly Valued between 0.15 and -2.34, Overvalued between 0.15 and 1.40, and Strongly Overvalued above 1.40. The current Forward EV/EBIT of -0.48 falls within the Historic Trend Line -Fairly Valued range.

1.09

InflaRx NV. (IFRX) has a current PS of 1.09. The 5-year average PS is 1860.76. The thresholds are as follows: Strongly Undervalued below -12487.85, Undervalued between -12487.85 and -5313.55, Fairly Valued between 9035.06 and -5313.55, Overvalued between 9035.06 and 16209.36, and Strongly Overvalued above 16209.36. The current Forward PS of 1.09 falls within the Historic Trend Line -Fairly Valued range.

-1.61

P/OCF

InflaRx NV. (IFRX) has a current P/OCF of -1.61. The 5-year average P/OCF is -2.32. The thresholds are as follows: Strongly Undervalued below -4.58, Undervalued between -4.58 and -3.45, Fairly Valued between -1.18 and -3.45, Overvalued between -1.18 and -0.05, and Strongly Overvalued above -0.05. The current Forward P/OCF of -1.61 falls within the Historic Trend Line -Fairly Valued range.

-1.51

P/FCF

InflaRx NV. (IFRX) has a current P/FCF of -1.51. The 5-year average P/FCF is -3.02. The thresholds are as follows: Strongly Undervalued below -9.33, Undervalued between -9.33 and -6.17, Fairly Valued between 0.14 and -6.17, Overvalued between 0.14 and 3.30, and Strongly Overvalued above 3.30. The current Forward P/FCF of -1.51 falls within the Historic Trend Line -Fairly Valued range.

InflaRx NV (IFRX) has a current Price-to-Book (P/B) ratio of 1.63. Compared to its 3-year average P/B ratio of 1.26 , the current P/B ratio is approximately 29.75% higher. Relative to its 5-year average P/B ratio of 1.18, the current P/B ratio is about 38.27% higher. InflaRx NV (IFRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -44.44%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -42.24% , the current FCF yield is about -100.00% lower.

1.63

P/B

Median3y

1.26

Median5y

1.18

-59.91

FCF Yield

Median3y

-44.44

Median5y

-42.24

Competitors Valuation Multiple

The average P/S ratio for IFRX's competitors is 3.25, providing a benchmark for relative valuation. InflaRx NV Corp (IFRX) exhibits a P/S ratio of 1.09, which is -66.41% above the industry average. Given its robust revenue growth of -80.75%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Unicycive Therapeutics Inc

5.14

114.55M

DTIL.O

Precision BioSciences Inc

Quince Therapeutics Inc

1.71

93.54M

ARTV.O

Artiva Biotherapeutics Inc

3.39

83.21M

HYFT.O

MindWalk Holdings Corp

2.31

27.82%

76.15M

Performance Decomposition

Market capitalization of IFRX decreased by 48.37% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -14.09K to -51.45K.

The secondary factor is the Revenue Growth, contributed -80.75%to the performance.

Overall, the performance of IFRX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-80.75%

123.82K → 23.83K

Revenue Growth

265.09%

-14.09K → -51.45K

Margin Expansion

-232.71%

1.32 → -1.75

P/E Change

-48.37%